1
NR 565 MIDTERM EXAM ADVANCED PHARMACOLOGY
2026/2027 | 2 Versions Complete Questions with Detailed
Verified Answers | 100% Correct | Pass Guaranteed - A+
Graded
[VERSION A - 80 QUESTIONS - 100% CORRECT]
[A1: Foundational Pharmacokinetics & Pharmacodynamics (Q1-15)]
Q1. A 68-year-old patient with cirrhosis and ascites is prescribed a hydrophilic drug
that is primarily renally eliminated. The APRN expects which pharmacokinetic
parameter to be most significantly altered?
A. Decreased volume of distribution due to reduced plasma protein binding
B. Increased volume of distribution due to expanded extracellular fluid volume
C. Decreased clearance due to reduced hepatic blood flow
D. Increased bioavailability due to decreased first-pass metabolism
B. Increased volume of distribution due to expanded extracellular fluid volume
[CORRECT]
Rationale: Ascites expands the extracellular fluid compartment, increasing the
volume of distribution (Vd) for hydrophilic drugs. While cirrhosis does reduce first-
pass metabolism (D) and hepatic clearance (C), the most significant alteration for a
hydrophilic, renally eliminated drug in this patient is the expanded Vd. Option A is
incorrect because reduced protein binding typically increases, not decreases, Vd.
Correct Answer: B
Q2. A patient taking a high-extraction drug (e.g., propranolol) develops congestive
heart failure, reducing hepatic blood flow by 40%. Which effect is most likely?
A. Decreased bioavailability due to increased first-pass extraction
B. Increased bioavailability due to decreased first-pass extraction
,2
C. No change in bioavailability because extraction ratio is independent of blood flow
D. Decreased half-life due to increased hepatic clearance
B. Increased bioavailability due to decreased first-pass extraction [CORRECT]
Rationale: High-extraction drugs (ER > 0.7) are highly dependent on hepatic blood
flow for clearance. Reduced hepatic blood flow in CHF decreases first-pass extraction,
thereby increasing bioavailability. Option A reverses the relationship; C is incorrect
because high-extraction drugs are flow-dependent; D is incorrect because clearance
decreases, prolonging half-life.
Correct Answer: B
Q3. A drug with a therapeutic index of 2 requires careful monitoring. Which
statement best describes the clinical significance?
A. The drug is very safe because the effective dose is twice the toxic dose
B. The drug is relatively unsafe because the toxic dose is only twice the effective dose
C. The therapeutic index has no relationship to safety margin
D. The drug requires loading doses because of low therapeutic index
B. The drug is relatively unsafe because the toxic dose is only twice the effective
dose [CORRECT]
Rationale: Therapeutic index (TI) = TD50/ED50. A TI of 2 indicates a narrow safety
margin where toxicity occurs at doses only twice the effective dose, necessitating
close monitoring. Option A reverses the interpretation; C is incorrect because TI
directly correlates with safety margin; D confuses TI with pharmacokinetic properties.
Correct Answer: B
Q4. A patient on chronic phenytoin therapy starts rifampin for tuberculosis
prophylaxis. Two weeks later, the phenytoin level is subtherapeutic. Which
mechanism explains this interaction?
A. Rifampin inhibits CYP2C9, reducing phenytoin metabolism
B. Rifampin induces CYP2C9 and CYP2C19, increasing phenytoin metabolism
,3
C. Rifampin displaces phenytoin from albumin, increasing free fraction
D. Rifampin reduces phenytoin absorption by chelation
B. Rifampin induces CYP2C9 and CYP2C19, increasing phenytoin metabolism
[CORRECT]
Rationale: Rifampin is a potent CYP450 inducer (CYP2C9, CYP2C19, CYP3A4) that
increases enzyme synthesis, accelerating phenytoin metabolism and lowering plasma
levels. Option A incorrectly states inhibition; C describes a protein-binding
interaction not characteristic of rifampin; D describes a chelation interaction not
applicable here.
Correct Answer: B
Q5. A drug follows first-order kinetics with a half-life of 6 hours. Approximately how
long will it take to reach 94% of steady-state concentration with a fixed dosing
schedule?
A. 6 hours
B. 12 hours
C. 18 hours
D. 24 hours
D. 24 hours [CORRECT]
Rationale: Steady-state is reached after approximately 4-5 half-lives. At 4 half-lives
(24 hours), 94% of steady-state is achieved (50% at 1 t½, 75% at 2 t½, 87.5% at 3 t½,
93.75% at 4 t½). Option A represents one half-life; B represents two; C represents
three.
Correct Answer: D
Q6. A patient receives a drug that follows zero-order kinetics at a dose of 100
mg/hour. The enzyme system responsible for metabolism becomes saturated at 80
mg/hour. What is the expected clinical outcome?
, 4
A. Plasma concentration will increase linearly with time
B. Plasma concentration will remain constant regardless of dose
C. Plasma concentration will decrease exponentially
D. A small dose increase will produce a proportional increase in plasma
concentration
A. Plasma concentration will increase linearly with time [CORRECT]
Rationale: Zero-order kinetics occurs when metabolic enzymes are saturated. Once
saturation occurs (at 80 mg/hour), additional drug accumulates linearly because
metabolism cannot increase proportionally, leading to potentially toxic accumulation.
Option B describes first-order at steady-state; C describes elimination; D describes
first-order kinetics.
Correct Answer: A
Q7. A lipophilic drug with high protein binding (98%) is prescribed to a patient with
hypoalbuminemia (albumin 2.1 g/dL). The APRN should be most concerned about:
A. Decreased volume of distribution leading to toxicity
B. Increased free fraction leading to enhanced pharmacologic effect and potential
toxicity
C. Decreased renal clearance due to reduced glomerular filtration
D. Increased hepatic metabolism due to increased drug delivery to the liver
B. Increased free fraction leading to enhanced pharmacologic effect and potential
toxicity [CORRECT]
Rationale: Reduced albumin decreases binding sites, increasing the free (unbound)
fraction of highly protein-bound drugs. While total drug concentration may appear
normal, the increased free fraction produces enhanced pharmacologic effects and
toxicity risk. Option A is incorrect because reduced binding increases Vd; C and D are
secondary effects but not the primary concern.
Correct Answer: B
NR 565 MIDTERM EXAM ADVANCED PHARMACOLOGY
2026/2027 | 2 Versions Complete Questions with Detailed
Verified Answers | 100% Correct | Pass Guaranteed - A+
Graded
[VERSION A - 80 QUESTIONS - 100% CORRECT]
[A1: Foundational Pharmacokinetics & Pharmacodynamics (Q1-15)]
Q1. A 68-year-old patient with cirrhosis and ascites is prescribed a hydrophilic drug
that is primarily renally eliminated. The APRN expects which pharmacokinetic
parameter to be most significantly altered?
A. Decreased volume of distribution due to reduced plasma protein binding
B. Increased volume of distribution due to expanded extracellular fluid volume
C. Decreased clearance due to reduced hepatic blood flow
D. Increased bioavailability due to decreased first-pass metabolism
B. Increased volume of distribution due to expanded extracellular fluid volume
[CORRECT]
Rationale: Ascites expands the extracellular fluid compartment, increasing the
volume of distribution (Vd) for hydrophilic drugs. While cirrhosis does reduce first-
pass metabolism (D) and hepatic clearance (C), the most significant alteration for a
hydrophilic, renally eliminated drug in this patient is the expanded Vd. Option A is
incorrect because reduced protein binding typically increases, not decreases, Vd.
Correct Answer: B
Q2. A patient taking a high-extraction drug (e.g., propranolol) develops congestive
heart failure, reducing hepatic blood flow by 40%. Which effect is most likely?
A. Decreased bioavailability due to increased first-pass extraction
B. Increased bioavailability due to decreased first-pass extraction
,2
C. No change in bioavailability because extraction ratio is independent of blood flow
D. Decreased half-life due to increased hepatic clearance
B. Increased bioavailability due to decreased first-pass extraction [CORRECT]
Rationale: High-extraction drugs (ER > 0.7) are highly dependent on hepatic blood
flow for clearance. Reduced hepatic blood flow in CHF decreases first-pass extraction,
thereby increasing bioavailability. Option A reverses the relationship; C is incorrect
because high-extraction drugs are flow-dependent; D is incorrect because clearance
decreases, prolonging half-life.
Correct Answer: B
Q3. A drug with a therapeutic index of 2 requires careful monitoring. Which
statement best describes the clinical significance?
A. The drug is very safe because the effective dose is twice the toxic dose
B. The drug is relatively unsafe because the toxic dose is only twice the effective dose
C. The therapeutic index has no relationship to safety margin
D. The drug requires loading doses because of low therapeutic index
B. The drug is relatively unsafe because the toxic dose is only twice the effective
dose [CORRECT]
Rationale: Therapeutic index (TI) = TD50/ED50. A TI of 2 indicates a narrow safety
margin where toxicity occurs at doses only twice the effective dose, necessitating
close monitoring. Option A reverses the interpretation; C is incorrect because TI
directly correlates with safety margin; D confuses TI with pharmacokinetic properties.
Correct Answer: B
Q4. A patient on chronic phenytoin therapy starts rifampin for tuberculosis
prophylaxis. Two weeks later, the phenytoin level is subtherapeutic. Which
mechanism explains this interaction?
A. Rifampin inhibits CYP2C9, reducing phenytoin metabolism
B. Rifampin induces CYP2C9 and CYP2C19, increasing phenytoin metabolism
,3
C. Rifampin displaces phenytoin from albumin, increasing free fraction
D. Rifampin reduces phenytoin absorption by chelation
B. Rifampin induces CYP2C9 and CYP2C19, increasing phenytoin metabolism
[CORRECT]
Rationale: Rifampin is a potent CYP450 inducer (CYP2C9, CYP2C19, CYP3A4) that
increases enzyme synthesis, accelerating phenytoin metabolism and lowering plasma
levels. Option A incorrectly states inhibition; C describes a protein-binding
interaction not characteristic of rifampin; D describes a chelation interaction not
applicable here.
Correct Answer: B
Q5. A drug follows first-order kinetics with a half-life of 6 hours. Approximately how
long will it take to reach 94% of steady-state concentration with a fixed dosing
schedule?
A. 6 hours
B. 12 hours
C. 18 hours
D. 24 hours
D. 24 hours [CORRECT]
Rationale: Steady-state is reached after approximately 4-5 half-lives. At 4 half-lives
(24 hours), 94% of steady-state is achieved (50% at 1 t½, 75% at 2 t½, 87.5% at 3 t½,
93.75% at 4 t½). Option A represents one half-life; B represents two; C represents
three.
Correct Answer: D
Q6. A patient receives a drug that follows zero-order kinetics at a dose of 100
mg/hour. The enzyme system responsible for metabolism becomes saturated at 80
mg/hour. What is the expected clinical outcome?
, 4
A. Plasma concentration will increase linearly with time
B. Plasma concentration will remain constant regardless of dose
C. Plasma concentration will decrease exponentially
D. A small dose increase will produce a proportional increase in plasma
concentration
A. Plasma concentration will increase linearly with time [CORRECT]
Rationale: Zero-order kinetics occurs when metabolic enzymes are saturated. Once
saturation occurs (at 80 mg/hour), additional drug accumulates linearly because
metabolism cannot increase proportionally, leading to potentially toxic accumulation.
Option B describes first-order at steady-state; C describes elimination; D describes
first-order kinetics.
Correct Answer: A
Q7. A lipophilic drug with high protein binding (98%) is prescribed to a patient with
hypoalbuminemia (albumin 2.1 g/dL). The APRN should be most concerned about:
A. Decreased volume of distribution leading to toxicity
B. Increased free fraction leading to enhanced pharmacologic effect and potential
toxicity
C. Decreased renal clearance due to reduced glomerular filtration
D. Increased hepatic metabolism due to increased drug delivery to the liver
B. Increased free fraction leading to enhanced pharmacologic effect and potential
toxicity [CORRECT]
Rationale: Reduced albumin decreases binding sites, increasing the free (unbound)
fraction of highly protein-bound drugs. While total drug concentration may appear
normal, the increased free fraction produces enhanced pharmacologic effects and
toxicity risk. Option A is incorrect because reduced binding increases Vd; C and D are
secondary effects but not the primary concern.
Correct Answer: B
